Intact Cell Mass Spectrometry for Embryonic Stem Cell Biotyping

Stem cells represent a unique cell type that is capable of self-renewal and differentiation into somatic cell types. Since the derivation of human embryonic stem cells and induced pluripotent stem cells, enormous potential has been recognized for disease modeling, drug development and regenerative medicine. Both embryonic stem cells and induced pluripotent stem cells possess the ability to differentiate into all three germ layers, hence they are naturally prone to respond to various differentiation stimuli. These inherent cellular fluctuations, which can result in risky phenotypic instability, must be addressed prior to introduction of these cells to human medicine, since they represent one of the major biosafety obstacles in the development of bio-industrial or clinical-grade stem cell cultures. Therefore, there is an ongoing need for novel robust, feasible and sensitive methods for determination and confirmation of the otherwise identical cells status, as well as for the detection of hidden divergences from their optimal state. A method of choice can be the intact cell mass spectrometry. Here we show how it can be applied in routine quality control of embryonic stem cell cultures

Generation of human iPSCs from fetal prostate fibroblasts HPrF

Human induced pluripotent stem cell line was generated from commercially available primary human prostate fibroblasts HPrF derived from a fetus, aged 18–24 weeks of gestation. The fibroblast cell line was reprogrammed with Yamanaka factors (OCT4, SOX2, c-MYC, KLF4) using CytoTune™-iPS 2.0 Sendai Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting the expression of factors of pluripotency on a single-cell level, and in vivo using teratoma formation assay. This iPS cell line will be a useful tool for studying both normal prostate development and prostate cancer disease

Generation of human iPSCs from human prostate cancer-associated fibroblasts IBPi002-A

A human induced pluripotent stem cell line was generated from cancer-associated fibroblasts of a 68-years old patient with diagnosed prostate adenocarcinoma (PCa). The fibroblast cell line was reprogrammed with Epi5™ Episomal iPSC Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting expression of factors of pluripotency on a single-cell level, and also in vivo using teratoma formation assay. This new iPS cell line may be used for differentiation into different prostate-specific cell types in differentiation studies